The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 87.50
Bid: 85.00
Ask: 90.00
Change: -2.50 (-2.78%)
Spread: 5.00 (5.882%)
Open: 90.00
High: 90.00
Low: 87.50
Prev. Close: 90.00
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Official Launch of Bleepa Box

23 Sep 2021 07:00

RNS Number : 6635M
Feedback PLC
23 September 2021
 

Feedback plc

 

RNS REACH

 

Feedback announces official launch of Bleepa Box to enable connected imaging in remote locations

 

· Enables capture and rapid transfer of medical images from remote locations to the Bleepa platform over mobile networks

· Images acquired in remote settings can be instantly reviewed by specialists in other locations, connected via the Bleepa platform for instant case discussion, enabling point of care patient management

· Multiple commercial opportunities including veterinary, international markets and the military

 

 

London, 23 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that following the success of the store and forward concept delivered in partnership with the equine division of CVS Group plc it is officially launching Bleepa Box, a specialist tool to enable image transfer from remote settings to the Bleepa platform.

 

Bleepa Box is a small tablet device that connects to imaging machines in order to securely push images to Bleepa over a mobile network from remote locations. Crucially Bleepa does not need WiFi access. Images are downloaded from the imaging machine onto the Bleepa Box then automatically pushed to Bleepa. The clinician who acquired the images can then review the images directly on the Bleepa Box and can make onward referrals or start a conversation with a specialist for input on the case whilst still in the remote location. This enables rapid decision making and treatment of the patient within that first visit, at the point of care, for cases that previously would have required transfer to treatment centres for imaging and management. This enables new capabilities around remote investigation and patient management, allowing patient imaging to be carried out and discussed in settings that were previously unreachable for traditional care models.

 

In addition to the veterinary imaging market which is growing at a compound annual growth rate of 6.7% and is expected to be worth an estimated £2.24bn in the UK1 by 2025, Bleepa Box's remote image capabilities are relevant to a number of other significant commercial opportunities including the delivery of rural imaging for TB screening services in India, as announced in our MOU with Qure.ai on 14 September 2021 and routes to support the military infield market.

 

Dr Tom Oakley, CEO of Feedback, said: "This technology was a solution created, designed and launched to support the work we are doing in the veterinary market with CVS and we are now taking the steps to formally build a brand around this capability. Imaging of horses is typically done in remote stables without WiFi, but there is often the need for timely advice and guidance by specialists whilst the vet is with the animal. We developed the store and forward technology that enables them to analyse and treat animals on site, which reduces the vet's workload, travel time and is certainly better for the animal. However, clearly there are other markets that have this requirement and formally branding the solution as Bleepa Box enables us to build a market around this capability across a range of industries. We anticipate that the product can be sold in combination with Bleepa or potentially as a standalone offering to facilitate image sharing to other third-party systems such as PACS."

 

Further information on Bleepa Box and the company's product focus can be found on the Company's website https://fbkmed.com/feedback-plc/reports-and-presentations/

 

1. Veterinary Imaging Market - Global Forecast to 2025 | MarketsandMarkets

 

-Ends-

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUUOVRAUUKUAR
Date   Source Headline
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.